Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03946527 · ClinicalTrials.gov registry record · Phase 2

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

A Phase 2 study of Pheochromocytoma and Paraganglioma, sponsored by Antonio Fojo.

Active
Registry status
Phase 2
Development phase
10
Enrollment target
2
Study locations

NCT03946527 is a Phase 2 study of Pheochromocytoma and Paraganglioma that is active but no longer recruiting, run by Antonio Fojo. The registered enrollment target is 10 participants, below the 519-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03946527, a Phase 2 study of Pheochromocytoma and Paraganglioma, is active but no longer recruiting, sponsored by Antonio Fojo.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

The objectives of this study are: * To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * To document the effects of lanreotide on markers of biochemical activity in participants with advanced or metastatic paraganglioma/ pheochromocytoma. Primary endpoints: • Assess efficacy by estimating the tumor growth rate while a patient is enrolled on study and comparing the growth rates on lanreotide to the pre-enrolment growth rate. Secondary endpoints include measurement of: * Overall survival (OS) * Progression-free survival (PFS) * Overall response rate (ORR) according to RECIST defined as partial response (PR) + complete response (CR) * Magnitude of reduction in levels of 24-hour urinary metanephrines, catecholamines and magnitude of reduction in serum chromogranin A, evaluated every two months while enrolled on study.

Conditions Studied

Pheochromocytoma Paraganglioma

Interventions

  • DRUG Lanreotide

Study Locations (2)

New York

  • Columbia University Irving Medical Center - New York

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2019-06-17
Est. Completion 2027-03
Phase Phase 2

Sponsor

Antonio Fojo

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03946527

The ClinicalTrials.gov registry entry for NCT03946527 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 519-participant average among 14 other Pheochromocytoma trials with a reported enrollment target (98% lower). The listed sponsor is Antonio Fojo, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Pheochromocytoma appearing as the primary indexed condition, and to 1 intervention - of which Lanreotide is the first listed.

NCT03946527 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT03946527 about?

NCT03946527 is a clinical study titled "LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)". The objectives of this study are: * To assess the efficacy of lanreotide given every 4 weeks in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * To assess the toxicity and safety of lanreotide in participants with advanced or metastatic paraganglioma/ pheochromocytoma. * ...

What is the current status of trial NCT03946527?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2019-06-17. Estimated completion is 2027-03.

What conditions does trial NCT03946527 study?

This clinical trial studies the following conditions: Pheochromocytoma, Paraganglioma.

What interventions are being tested in trial NCT03946527?

The interventions under investigation include: Lanreotide (DRUG).

Who is sponsoring clinical trial NCT03946527?

This trial is sponsored by Antonio Fojo, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03946527 being conducted?

This trial has 2 study locations across New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pheochromocytoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pheochromocytoma

All registered trials for this condition

Paraganglioma

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.